Search Result

Results for "

androgen receptor (AR)

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Androgen Receptor (109) 5 alpha Reductase (5) Apoptosis (12) Aryl Hydrocarbon Receptor (1) Autophagy (8) Bacterial (1) Drug Metabolite (2) E3 Ligase Ligand-Linker Conjugates (1) Epigenetic Reader Domain (3) Estrogen Receptor/ERR (1) Fungal (6) Glucocorticoid Receptor (2) Histone Acetyltransferase (2) Isotope-Labeled Compounds (7) Ligands for E3 Ligase (3) Ligands for Target Protein for PROTAC (4) Mineralocorticoid Receptor (4) MNK (1) NF-κB (1) NO Synthase (1) p38 MAPK (1) Parasite (2) PPAR (2) Progesterone Receptor (2) Prostaglandin Receptor (1) PROTAC Linkers (2) PROTACs (17) SNIPERs (2)
By Research Areas:	Cancer (105) Cardiovascular Disease (4) Endocrinology (23) Infection (7) Inflammation/Immunology (6) Metabolic Disease (3)

By Targets:

Androgen Receptor (109)

5 alpha Reductase (5)

Apoptosis (12)

Aryl Hydrocarbon Receptor (1)

Autophagy (8)

Bacterial (1)

Drug Metabolite (2)

E3 Ligase Ligand-Linker Conjugates (1)

Epigenetic Reader Domain (3)

Estrogen Receptor/ERR (1)

Fungal (6)

Glucocorticoid Receptor (2)

Histone Acetyltransferase (2)

Isotope-Labeled Compounds (7)

Ligands for E3 Ligase (3)

Ligands for Target Protein for PROTAC (4)

Mineralocorticoid Receptor (4)

MNK (1)

NF-κB (1)

NO Synthase (1)

p38 MAPK (1)

Parasite (2)

PPAR (2)

Progesterone Receptor (2)

Prostaglandin Receptor (1)

PROTAC Linkers (2)

PROTACs (17)

SNIPERs (2)

By Research Areas:

Cancer (105)

Cardiovascular Disease (4)

Endocrinology (23)

Infection (7)

Inflammation/Immunology (6)

Metabolic Disease (3)

134

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: Androgen Receptor

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-120018

VPC-13566	Androgen Receptor	Cancer
VPC-13566, a BF3-specific small molecule, is an **androgen receptor (AR)** inhibitor. VPC-13566 is effective in inhibiting AR transcriptional activity in vitro as well as the growth of AR-dependent PCa cell lines. VPC-13566 can be used as a chemical probe to help identify unknown AR partners.VPC-13566 can be used for the research of cancer.

HY-149862

ARD-2051	PROTACs Androgen Receptor	Cancer
ARD-2051 is a potent and orally active androgen receptor *(AR)* proteolysis-targeting chimera degrader. ARD-2051 achieves DC₅₀ values of 0.6 nM for AR protein degradation in both the LNCaP and VCaP prostate cancer cell lines. ARD-2051 can be used for the research of prostate cancer .

HY-12111

BMS-564929

5 Publications Verification

Androgen Receptor Endocrinology

BMS-564929 is an androgen receptor (AR) agonist, binds to androgen receptor (AR) with a K_i of 2.11±0.16 nM.

BMS-564929 5 Publications Verification	Androgen Receptor	Endocrinology
BMS-564929 is an **androgen receptor** (AR) agonist, binds to androgen receptor (AR) with a K_i of 2.11±0.16 nM.

HY-103246

TFM-4AS-1	Androgen Receptor	Cancer
TFM-4AS-1 is a *selective androgen* receptor modulator (SARM). TFM-4AS-1 is a potent androgen receptor (AR) ligand with an IC₅₀** of 38 nm. TFM-4AS-1 is also a gene-selective agonist .

HY-146027

Androgen receptor antagonist 4	Androgen Receptor	Cancer
Androgen receptor antagonist 4 (Compound AT2) is an **androgen receptor (AR) antagonist with an IC₅₀** of 0.15 μM. Androgen receptor antagonist 4 efficiently antagonizes AR transcriptional activity, suppresses downstream target gene of AR, and blocks the DHT-induced AR nuclear translocation. Androgen receptor antagonist 4 shows anticancer activities .

HY-146494

Androgen receptor antagonist 5	Androgen Receptor	Cancer
Androgen receptor antagonist 5 (compound 42f) is a potent **androgen receptor (AR) antagonist with an IC₅₀** value of 6.17 μM. Androgen receptor antagonist 5 can effectively impair AR nuclear translocation, reducing the levels of nuclear AR, and disrupts AR-mediated gene regulation. Androgen receptor antagonist 5 has antiproliferative activity against LNCaP and exhibits antitumor activity in LNCaP xenograft tumor mice model. Androgen receptor antagonist 5 can be used for researching prostate cancer .

HY-130992

Androgen receptor antagonist 1	Androgen Receptor Ligands for Target Protein for PROTAC	Cancer
Androgen receptor antagonist 1 is an orally available full **androgen receptor** (AR) antagonist with an IC₅₀ of 59 nM . Androgen receptor antagonist 1 (Compound 6) can be used in the synthesis of PROTAC AR degraders, which results 24% and 47 % AR protein degradation in LNCaP cells at 1 μM and 10 μM, respectively .

HY-146026

Androgen receptor antagonist 3	Androgen Receptor	Cancer
Androgen receptor antagonist 3 (Compound C18) is an **androgen receptor (AR) antagonist with an IC₅₀** of 2.4 μM. Androgen receptor antagonist 3 shows anticancer activities .

HY-152524

Androgen receptor antagonist 7	Androgen Receptor	Cancer
Androgen receptor antagonist 7 is an effective **androgen receptor** (AR) antagonist with an IC₅₀ value of 1.18 µM. Androgen receptor antagonist 7 has biological activity in vitro and inhibits the expression of AR target in a time and dose dependent manner with an GI₅₀ value of 7.9 µM .

HY-131953

Androgen receptor-IN-3	Androgen Receptor	Cancer
Androgen receptor-IN-3 (Compound 22) is an **androgen receptor** inhibitor. Androgen receptor-IN-3 inhibits AR-driven transcriptional activity in LNCaP cells, with an IC₅₀ of 5.04 μM .

HY-160692

AR antagonist 7

Androgen Receptor Others

AR antagonist 7 (86) is an androgen receptor (AR) antagonist that can be used in the research of hair loss .

AR antagonist 7	Androgen Receptor	Others
AR antagonist 7 (86) is an androgen receptor (AR) antagonist that can be used in the research of hair loss .

HY-16060

Apalutamide 5+ Cited Publications ARN-509	Androgen Receptor	Cancer
Apalutamide (ARN-509) is a potent and competitive **androgen receptor** (AR) antagonist, binding AR with an IC₅₀ of 16 nM .

HY-117669

VPC-14228	Androgen Receptor	Cancer
VPC-14228 is a potent androgen receptor DNA binding domain (AR-DBD) inhibitor that interferes with the interaction of AR with androgen response elements and effectively blocks AR transcriptional activity. VPC-14228 can be used in prostate cancer research .

HY-112895

UT-155

2 Publications Verification

Androgen Receptor Cancer

UT-155 is a selective and potent androgen receptor (AR) antagonist, with a K_i of 267 nM for UT-155 binding to AR-LBD.

UT-155 2 Publications Verification	Androgen Receptor	Cancer
UT-155 is a selective and potent androgen receptor *(AR)* antagonist, with a K_i of 267 nM for UT-155 binding to AR-LBD.

HY-136596

Apalutamide-COOH	Drug Metabolite	Cancer
Apalutamide-COOH is a metabolite of Apalutamide. Apalutamide is a potent and competitive **androgen receptor** (AR) antagonist, binding AR with an IC₅₀ of 16 nM .

HY-163641

AR Degrader-1	Androgen Receptor	Cancer
AR Degrader-1 is an **androgen receptor** (AR) monovalent degrader. AR Degrader-1 degrades AR without obvious cytotoxicity in LNCaP prostate cancer cells .

HY-15758

3,3'-Diindolylmethane

5+ Cited Publications

DIM; Arundine; HB 236
Androgen Receptor Autophagy Cancer

3,3'-Diindolylmethane is a strong, pure androgen receptor (AR) antagonist.

3,3'-Diindolylmethane 5+ Cited Publications DIM; Arundine; HB 236	Androgen Receptor Autophagy	Cancer
3,3'-Diindolylmethane is a strong, pure **androgen receptor** (AR) antagonist.

HY-142923

AR antagonist 2	Androgen Receptor	Cancer
AR antagonist 2 (compound 58) is a potent **androgen receptor (AR) inhibitor with an IC₅₀** of 0.95 μM. AR antagonist 2 has the potential for cancer research .

HY-135732

SK33	Androgen Receptor	Cancer
SK33, a trifluoromethylated enobosarm analog, is a potent, and tissue selective anti-androgen. SK33reduces androgen receptor (AR) transcriptional activity .

HY-16079

AZD3514 2 Publications Verification	Androgen Receptor	Cancer
AZD3514 is an orally activie and selective **androgen receptor (AR)** inhibitor. AZD3514 androgen-dependently and -independently inhibits AR signal. AZD351 down-regulates nuclear AR levels in human LNCaP prostate cancer cells in the absence of androgen with an pIC₅₀ value of 5.75. AZD3514 can be used for the research of prostate cancer .

HY-163485

AR antagonist 8	Androgen Receptor	Endocrinology
AR antagonist 8 (compound 16) is a potent Lupeol-inspired **androgen receptor (AR) antagonist with an IC₅₀** of 0.76 μM. AR antagonist 8 is a uniquely substituted unnatural entestrane .

HY-151266

AR antagonist 4	Androgen Receptor	Cancer
AR antagonist 4 (Compound 67-b) is an orally active **androgen receptor (AR) antagonist with an IC₅₀ of 246.6 nM against wt-AR, and is also an AR degrader with a DC₅₀** of 2.84 μM .

HY-105122

Zanoterone WIN 49596	Androgen Receptor	Endocrinology Cancer
Zanoterone is an orally active antagonist of the **androgen receptor (AR) with a K_i** of 2.2 μM. Zanoterone blocks the binding of androgens such as testosterone and dihydrotestosterone (DHT), inhibiting the androgen signaling pathway, thereby reducing androgen-dependent prostate hyperplasia and prostate cancer growth .

HY-123310

JNJ-26146900	Androgen Receptor	Cancer
JNJ-26146900 is a potent and orally active **androgen receptor antagonist with a K_i** value of 400nM for rat AR. JNJ-26146900 is a nonsteroidal androgen receptor (AR) ligand. JNJ-26146900 reduces prostate tumor size and prevents bone loss. JNJ-26146900 can be used in research of cancer .

HY-11027

MK-0773

4 Publications Verification

PF-05314882
Androgen Receptor Endocrinology

MK-0773 is a selective androgen receptor modulators (SARMs) that binds to AR with an IC₅₀ of 6.6 nM.

MK-0773 4 Publications Verification PF-05314882	Androgen Receptor	Endocrinology
MK-0773 is a *selective androgen* receptor modulators (SARMs) that binds to AR with an IC₅₀** of 6.6 nM.

HY-16060S

Apalutamide-d4 ARN-509-d₄	Androgen Receptor	Cancer
Apalutamide-d₄ is a deuterium labeled Apalutamide. Apalutamide is a potent and competitive androgen receptor (AR) antagonist, binding AR with an IC50 of 16 nM[1].

HY-160680

AR antagonist 6	Androgen Receptor	Endocrinology
AR antagonist 6 (compound 6i) is a diphenyl ether androgen receptor (AR) antagonist that binds AR at a concentration of 120 nM. AR antagonist 6 exhibits low toxicity and in vitro activity against the golden Syrian hamster ear model. .

HY-143535

HG122

Androgen Receptor Cancer

HG122 promotes androgen receptor (AR) degradation through the proteasome pathway inhibiting the castration-resistant prostate cancer.

HG122	Androgen Receptor	Cancer
HG122 promotes **androgen receptor (AR)** degradation through the proteasome pathway inhibiting the castration-resistant prostate cancer.

HY-157455

AR antagonist 5	Androgen Receptor	Cancer
AR antagonist 5 (compound 30a) is a selective androgen receptor (AR) antagonist with an IC₅₀ value of 134.8 nM. AR antagonist 5 has favorable pharmacokinetic properties and shows a high skin exposure and low plasma exposure ^[1.

HY-114402

ARD-69	Androgen Receptor PROTACs	Cancer
ARD-69 (compound 34) is a potent PROTAC androgen receptor degrader. ARD-69 induces degradation of androgen receptor (AR) protein in AR-positive prostate cancer cell lines. ARD-69 suppresses AR-regulated gene expression . ARD-69 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-138641

Bavdegalutamide 2 Publications Verification ARV-110	Androgen Receptor	Cancer
Bavdegalutamide (ARV-110) is an orally active, specific **androgen receptor (AR)** PROTAC degrader. Bavdegalutamide promotes ubiquitination and degradation of AR. Bavdegalutamide can be used for the research of prostate cancer .

HY-14249

Bicalutamide 10+ Cited Publications	Androgen Receptor Autophagy	Cancer
Bicalutamide is an orally active non-steroidal **androgen receptor (AR)** antagonist. Bicalutamide can be used for the research of prostate cancer .

HY-70002B

Enzalutamide carboxylic acid 1 Publications Verification MDV3100 carboxylic acid	Drug Metabolite	Cancer
Enzalutamide carboxylic acid (MDV3100 carboxylic acid) is an inactive metabolite of Enzalutamide (MDV3100). Enzalutamide is an androgen receptor (AR) antagonist .

HY-162241

SJH1-62B

PROTACs Others

SJH1-62B is a proteolysis targeting chimera (PROTAC) that can target the androgen receptor (AR) .

SJH1-62B	PROTACs	Others
SJH1-62B is a proteolysis targeting chimera (PROTAC) that can target the androgen receptor (AR) .

HY-N1943

Ailanthone Δ13-Dehydrochaparrinone	Androgen Receptor	Inflammation/Immunology Cancer
Ailanthone (Δ13-Dehydrochaparrinone) is a potent inhibitor of both full-length **androgen receptor (AR) (IC₅₀*=69 nM) and constitutively active truncated AR splice variants (AR_1-651* IC₅₀=309 nM).

HY-N9917

Galloylalbiflorin 6′-O-Galloylalbiflorin	Androgen Receptor	Endocrinology Cancer
Galloylalbiflorin (6′-O-Galloylalbiflorin) is an **androgen receptor** (AR) antagonist (IC₅₀=53.3 μM) and can be found in the roots of Paeonia lactiflora. Galloylalbiflorin shows anti-androgens activity .

HY-16060S3

Apalutamide-d7 ARN-509-d₇	Androgen Receptor Isotope-Labeled Compounds	Cancer
Apalutamide-d₇ is deuterated labeled Apalutamide (HY-16060). Apalutamide (ARN-509) is a potent and competitive **androgen receptor** (AR) antagonist, binding AR with an IC₅₀ of 16 nM .

HY-16060R

Apalutamide (Standard)	Androgen Receptor	Cancer
Apalutamide (Standard) is the analytical standard of Apalutamide. This product is intended for research and analytical applications. Apalutamide (ARN-509) is a potent and competitive **androgen receptor** (AR) antagonist, binding AR with an IC₅₀ of 16 nM .

HY-70002

Enzalutamide Maximum Cited Publications 138 Publications Verification MDV3100	Androgen Receptor Autophagy	Cancer
Enzalutamide (MDV3100) is an **androgen receptor (AR) antagonist with an IC₅₀ of 36 nM in LNCaP prostate cells. Enzalutamide is an autophagy** activator .

HY-16985

Darolutamide 5 Publications Verification ODM-201; BAY-1841788	Androgen Receptor	Cancer
Darolutamide (ODM-201;BAY-1841788) is a potent androgen receptor (AR) antagonist with an IC₅₀ of 26 nM in in vitro assay.

HY-16060S1

Apalutamide-d3 ARN-509-d₃	Androgen Receptor	Cancer
Apalutamide-d₃ is the deuterium labeled Apalutamide[1]. Apalutamide (ARN-509) is a potent and competitive androgen receptor (AR) antagonist, binding AR with an IC50 of 16 nM[2].

HY-W653723

N-Nitrosodicyclohexylamine NDCHA	Androgen Receptor	Endocrinology
N-Nitrosodicyclohexylamine (NDCHA) is a N-nitrosocompound with anti-androgenic activities. N-Nitrosodicyclohexylamine shows the competitive binding to **androgen receptor (AR)** against 5α-dihydrotestosterone and decreased the level of AR protein .

HY-131388

ABM-14	Ligands for Target Protein for PROTAC	Cancer
ABM-14 is a ligand for targeting **androgen receptor (AR)** for PROTAC. ABM-14 binds to a ligand for VHL via linker to form ARCC-4 (HY-130492) to degrade AR .

HY-156111

ARD-1676	PROTACs Androgen Receptor	Cancer
ARD-1676 is an orally available androgen receptor (AR) PROTAC degrader, consisting of AR ligand and cereblon ligand. ARD-1676 has AR-degrading activity in vitro and in vivo and inhibits VCaP tumor growth in mouse xenograft tumor models .

HY-158101

BMS-986365 CC-94676	Androgen Receptor	Cancer
BMS-986365 is a selective heterobifunctional ligand-directed degrader (LDD) targeting the androgen receptor (AR). BMS-986365 demonstrated significant in vivo potency, degrading AR, inhibiting AR signaling, and inhibiting tumor growth in animal models of advanced prostate cancer.

HY-144127

AR antagonist 3	Androgen Receptor	Cancer
AR antagonist 3 is a potent and selective **androgen receptor (AR) antagonist with an IC₅₀** of 0.47 µM. AR antagonist 3 exhibits a dose-dependent decrease of the FRET signal (IC₅₀= 18.05 μM). AR antagonist 3 shows effective inhibition on tumor growth when administered intratumorally .

HY-111848A

PROTAC AR Degrader-4 TFA	SNIPERs PROTACs Androgen Receptor	Cancer
PROTAC AR Degrader-4 comprises a IAP ligand binding group, a linker and an **Androgen Receptor** (AR) binding group. PROTAC AR Degrader-4 is an AR degrader. Degradation inducers based on cIAP1 are called specific and non-genetic IAP-dependent protein erasers (SNIPERs) .

HY-111848

PROTAC AR Degrader-4	SNIPERs PROTACs Androgen Receptor	Cancer
PROTAC AR Degrader-4 comprises a IAP ligand binding group, a linker and an **Androgen Receptor** (AR) binding group. PROTAC AR Degrader-4 is an AR degrader. Degradation inducers based on cIAP1 are called specific and non-genetic IAP-dependent protein erasers (SNIPERs) .

HY-130845

AR antagonist 1	Ligands for E3 Ligase Ligands for Target Protein for PROTAC	Cancer
AR antagonist 1 (compound 29) is a potent **androgen receptor (AR) antagonist and binds to E3 ligase ligands with weak binding affinities to VHL protein in the synthesis of PROTAC** ARD-266 (HY-133020).

HY-149433

BWA-522	Androgen Receptor Apoptosis	Cancer
BWA-522 is an orally available small molecule protein-targeting chimera (PROTACs) with significant degradation effect on AR-FL and AR-V7. BWA-522 antagonizes the N-terminal domain (AR-NTD) of the androgen receptor (Androgen Receptor) and induces apoptosis in PC cells. BWA-522 inhibits tumor growth in LNCaP xenograft model studies (60 mg/kg, po; TGI=76%). The efficiencies of BWA-522 in degrading AR-V7 and AR-FL were 77.3% (1 μM) and 72.0% (5 μM) in VCaP and LNCaP cells, respectively .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-15758

3,3'-Diindolylmethane Maximum Cited Publications 8 Publications Verification DIM; Arundine; HB 236	Alkaloids other families Classification of Application Fields Source classification Plants Disease Research Fields Alkaloid Dimers Cancer	Androgen Receptor Autophagy
3,3'-Diindolylmethane is a strong, pure **androgen receptor** (AR) antagonist.

HY-N1943

Ailanthone Δ13-Dehydrochaparrinone	Structural Classification Simaroubaceae Ailanthus altissima (Mill.) Swingle Classification of Application Fields Terpenoids Source classification Diterpenoids Plants Inflammation/Immunology Disease Research Fields	Androgen Receptor
Ailanthone (Δ13-Dehydrochaparrinone) is a potent inhibitor of both full-length **androgen receptor (AR) (IC₅₀*=69 nM) and constitutively active truncated AR splice variants (AR_1-651* IC₅₀=309 nM).

HY-N0790

Lupeol 3 Publications Verification Clerodol; Monogynol B; Fagarasterol	Triterpenes Structural Classification other families Classification of Application Fields Terpenoids Source classification Plants Disease Research Fields Cancer	Androgen Receptor Apoptosis
Lupeol (Clerodol; Monogynol B; Fagarasterol) is an active pentacyclic triterpenoid, has anti-oxidant, anti-mutagenic, anti-tumor and anti-inflammatory activity. Lupeol is a potent androgen **receptor (AR)** inhibitor and can be used for cancer research, especially prostate cancer of androgen-dependent phenotype (ADPC) and castration resistant phenotype (CRPC) .

HY-N7045

Isosilybin B 1 Publications Verification	Flavanonols Flavonoids Glycine soya Classification of Application Fields Source classification Phenols Polyphenols Cyamopsis tetragonoloba (L.) Taub. Plants Compositae Disease Research Fields Cancer	Androgen Receptor Apoptosis
Isosilybin B, a flavonolignan isolated from Silybum marianum, has anti-prostate cancer (PCA) activity via inhibiting proliferation and inducing G1 phase arrest and apoptosis. Isosilybin B causes **androgen receptor (AR)** degradation .

HY-N9917

Galloylalbiflorin 6′-O-Galloylalbiflorin	Paeonia lactiflora Pall. Source classification Polyphenols Plants Paeoniaceae	Androgen Receptor
Galloylalbiflorin (6′-O-Galloylalbiflorin) is an **androgen receptor** (AR) antagonist (IC₅₀=53.3 μM) and can be found in the roots of Paeonia lactiflora. Galloylalbiflorin shows anti-androgens activity .

HY-N7043

Isosilybin A 1 Publications Verification	Flavanonols Flavonoids Glycine soya Classification of Application Fields Source classification Phenols Polyphenols Cyamopsis tetragonoloba (L.) Taub. Plants Compositae Disease Research Fields Cancer	Apoptosis
Isosilybin A, a flavonolignan isolated from silymarin, has anti-prostate cancer (PCA) activity. Isosilybin A inhibits proliferation and induces G1 phase arrest and apoptosis in cancer cells, which activates apoptotic machinery in PCA cells via targeting Akt-NF-κB-androgen receptor (AR) axis .

HY-N2908

Atraric acid Methyl atrarate	Structural Classification Microorganisms Classification of Application Fields Phenols Essence, Fragrance Cosmetic Research Plants Inflammation/Immunology Disease Research Fields Cancer	Androgen Receptor NO Synthase p38 MAPK NF-κB
Atraric acid (Methyl atrarate) is a specific **androgen receptor (AR) antagonist with anti-inflammatory and anticancer effects. Atraric acid represses the expression of the endogenous prostate specific antigen gene in both LNCaP and C4-2 cells. Atraric acid can also inhibit the synthesis of NO and cytokine, and suppress the MAPK-NFκB** signaling pathway. Atraric acid can be used to research prostate diseases and inflammatory diseases .

Cat. No.	Product Name	Chemical Structure

HY-16060S

Apalutamide-d4

Apalutamide-d₄ is a deuterium labeled Apalutamide. Apalutamide is a potent and competitive androgen receptor (AR) antagonist, binding AR with an IC50 of 16 nM[1].
HY-70002S1

Enzalutamide-d6

Enzalutamide-d₆ is a deuterium labeled Enzalutamide (MDV3100). Enzalutamide is an androgen receptor (AR) antagonist with an IC50 of 36 nM in LNCaP prostate cells[1].

HY-16060S3

Apalutamide-d7
Apalutamide-d₇ is deuterated labeled Apalutamide (HY-16060). Apalutamide (ARN-509) is a potent and competitive **androgen receptor** (AR) antagonist, binding AR with an IC₅₀ of 16 nM .

HY-16060S1

Apalutamide-d3
Apalutamide-d₃ is the deuterium labeled Apalutamide[1]. Apalutamide (ARN-509) is a potent and competitive androgen receptor (AR) antagonist, binding AR with an IC50 of 16 nM[2].

HY-16060S2

Apalutamide-13C,d3
Apalutamide- ¹³C,d₃ is the ¹³C- and deuterium labeled Apalutamide. Apalutamide (ARN-509) is a potent and competitive androgen receptor (AR) antagonist, binding AR with an IC50 of 16 nM[1].

HY-70002S

Deutenzalutamide
Deutenzalutamide (Enzalutamide-d₃) is a developed deuterium labeled Enzalutamide (MDV3100). Enzalutamide is an androgen receptor (AR) antagonist with an IC50 of 36 nM in LNCaP prostate cells .

HY-14249S

Bicalutamide-d4
Bicalutamide-d₄ is the deuterium labeled Bicalutamide. Bicalutamide is an orally active non-steroidal androgen receptor (AR) antagonist. Bicalutamide can be used for the research of prostate cancer[1].

HY-135794S

11-Ketodihydrotestosterone-d3

11-Ketodihydrotestosterone-d₃ is the deuterium labeled 11-Ketodihydrotestosterone. 11-Ketodihydrotestosterone (11-KDHT; 5α-Dihydro-11-keto testosterone) is an endogenous steroid and a metabolite of 11β-Hydroxyandrostenedione. 11-Ketodihydrotestosterone is an active androgen and is also a potent androgen receptor (AR) agonist with a Ki of 20.4 nM and an EC50 of 1.35 nM for human AR. 11-Ketodihydrotestosterone drives gene regulation, protein expression and cell growth in androgen-dependent prostate cancer cells[1][2].

HY-14249S1

Bicalutamide-d5
Bicalutamide-d₅ is deuterated labeled Bicalutamide (HY-14249). Bicalutamide is an orally active non-steroidal **androgen receptor (AR)** antagonist. Bicalutamide can be used for the research of prostate cancer .

HY-13613S

Dutasteride-13C6
Dutasteride- ¹³C₆ is the ¹³C labeled Dutasteride[1]. Dutasteride (GG745) is a potent inhibitor of both 5α-reductase isozymes. Dutasteride may possess off-target effects on the androgen receptor (AR) due to its structural similarity to DHT[2].

HY-13613S2

Dutasteride-13C,15N,d
Dutasteride- ¹³C, ¹⁵N,d is ¹⁵N and deuterated labeled Dutasteride (HY-13613). Dutasteride (GG745) is a potent inhibitor of both 5α-reductase isozymes. Dutasteride may possess off-target effects on the androgen receptor (AR) due to its structural similarity to DHT .

HY-111372S

Finerenone-d3

Finerenone-d3 is the deuterium labeled finerenone (HY-111372). Finerenone is a third-generation, selective, and orally available nonsteroidal mineralocorticoid receptor (MR) antagonist (IC₅₀=18 nM). Finerenone displays excellent selectivity versus glucocorticoid receptor (GR), androgen receptor (AR), and progesterone receptor (>500-fold). Finerenone has the potential for cardiorenal diseases research, such as type 2 diabetes mellitus and chronic kidney disease .

HY-B0846S

Dimethomorph-d8
Dimethomorph-d₈ is the deuterium labeled Dimethomorph[1]. Dimethomorph is a fungicide belongs to the fungicide group of sterol biosynthesis inhibitor. Dimethomorph can inhibit fungal cell wall formation. Dimethomorph also inhibits androgen receptor (AR) activity in MDA-kb2 cells with an IC20 of 0.263 μM[2][3][4].

HY-116214S1

Cyprodinil-13C6

Cyprodinil- ¹³C₆ is the ¹³C₆ labeled Cyprodinil. Cyprodinil is an anilinopyrimidine broad-spectrum fungicide that inhibits the biosynthesis of methionine in phytopathogenic fungi. Cyprodinil inhibits mycelial cell growth of B. cinerea, P. herpotrichoides, and H. oryzae on amino acid-free media (IC₅₀s=0.44, 4.8, and 0.03 µM, respectively). Cyprodinil acts as an androgen receptor (AR) agonist (EC50=1.91 µM) in the absence of the AR agonist DHT and inhibits the androgenic effect of DHT (IC50=15.1 µM).

HY-116214S

Cyprodinil-d5

Cyprodinil-d₅is the deuterium labeledCyprodinil(HY-116214) . Cyprodinil is an anilinopyrimidine broad-spectrum fungicide that inhibits the biosynthesis of methionine in phytopathogenic fungi. Cyprodinil inhibits mycelial cell growth of B. cinerea, P. herpotrichoides, and H. oryzae on amino acid-free media (IC₅₀s=0.44, 4.8, and 0.03 μM, respectively). Cyprodinil acts as an androgen receptor (AR) agonist (EC₅₀=1.91 μM) in the absence of the AR agonist DHT and inhibits the androgenic effect of DHT (IC₅₀=15.1 μM) .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks